Clinical Trials · NCT00254254
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 13
- Start date
- Feb 2006
- Locations
- 5 sites, United States
- Primary endpoint
- To assess the pharmacokinetics of exenatide